Celldex Therapeutics Q3 EPS $(0.75) Beats $(0.84) Estimate

Celldex Therapeutics (NASDAQ:CLDX) reported quarterly losses of $(0.75) per share which beat the analyst consensus estimate of $(0.84) by 10.71 percent. This is a 1775 percent decrease over losses of $(0.04) per share

Benzinga · 11/12/2019 13:28

Celldex Therapeutics (NASDAQ:CLDX) reported quarterly losses of $(0.75) per share which beat the analyst consensus estimate of $(0.84) by 10.71 percent. This is a 1775 percent decrease over losses of $(0.04) per share from the same period last year.